-$0.15 Earnings Per Share Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter

Share on StockTwits

Wall Street brokerages forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.13). Pieris Pharmaceuticals reported earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 14th.

On average, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.44). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($0.95) to ($0.59). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The company had revenue of $11.69 million for the quarter, compared to the consensus estimate of $13.46 million.

A number of brokerages recently commented on PIRS. HC Wainwright set a $12.00 price target on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. BidaskClub raised shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $12.33.

Shares of PIRS traded down $0.10 during midday trading on Tuesday, hitting $5.20. 248,677 shares of the company traded hands, compared to its average volume of 375,564. Pieris Pharmaceuticals has a 52 week low of $4.43 and a 52 week high of $9.75.

In other news, Director Christopher P. Kiritsy acquired 5,000 shares of the firm’s stock in a transaction on Friday, September 14th. The stock was acquired at an average price of $5.11 per share, with a total value of $25,550.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $51,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.07% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Pieris Pharmaceuticals by 49.1% during the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after acquiring an additional 884,348 shares during the period. Acadian Asset Management LLC increased its position in shares of Pieris Pharmaceuticals by 45.5% during the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock worth $10,773,000 after acquiring an additional 664,032 shares during the period. Aquilo Capital Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $10,013,000. Millennium Management LLC increased its position in shares of Pieris Pharmaceuticals by 160.7% during the first quarter. Millennium Management LLC now owns 1,824,109 shares of the biotechnology company’s stock worth $12,440,000 after acquiring an additional 1,124,338 shares during the period. Finally, Prosight Management LP increased its position in shares of Pieris Pharmaceuticals by 141.2% during the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock worth $6,895,000 after acquiring an additional 796,237 shares during the period. 64.89% of the stock is currently owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MediBloc [MEDX]  Achieves Market Capitalization of $0.00
MediBloc [MEDX] Achieves Market Capitalization of $0.00
athenahealth  Downgraded to “Outperform” at Evercore ISI
athenahealth Downgraded to “Outperform” at Evercore ISI
Cooper Tire & Rubber  Raised to “Market Perform” at Wolfe Research
Cooper Tire & Rubber Raised to “Market Perform” at Wolfe Research
Scientific Games  Price Target Lowered to $26.00 at Deutsche Bank
Scientific Games Price Target Lowered to $26.00 at Deutsche Bank
Citigroup Raises Juniper Networks  Price Target to $32.00
Citigroup Raises Juniper Networks Price Target to $32.00
Mesoblast  Given Buy Rating at Maxim Group
Mesoblast Given Buy Rating at Maxim Group


© 2006-2018 Ticker Report